A Phase 1 Study of PBCAR19B in Subjects with CD19-expressing Malignancies
Sponsor: |
Precision BioSciences, Inc. |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAT5943 |
U.S. Govt. ID: |
NCT04649112 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
The purpose of this research study is to obtain information on the safety and effectiveness of PBCAR19B to treat certain types of cancers. PBCAR19B is a new investigational treatment for certain types of cancer of the blood, such as leukemia and lymphoma. It is made from a type of blood cells known as T cells. The T cells in PBCAR19B came from healthy people who have donated their blood. The donated T cells have been genetically changed, so that they may be able to kill some types of cancer cells.
Investigator
Ran Reshef, MD
Are you age 18 or older? |
Yes |
No |
Do you have lymphoma that has come back or not responded to treatment? |
Yes |
No |
Are you able and willing to provide written informed consent? |
Yes |
No |